Cure My Disease

Don't miss your cure!

 Log in / Sign up

One stool sample, two cancers: europe tests combined screening

NCT ID NCT07873580

Diagnosis Sponsor: University of Latvia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 14, 2026 · Last updated Oct 15, 2026 · Updated 1 time

Summary

Researchers across Europe are studying whether stomach cancer screening can be added to existing bowel cancer screening programs. Adults aged 50 and older who are due for bowel cancer screening are invited to provide a stool sample that is tested for both colorectal cancer and Helicobacter pylori, a bacterium linked to stomach cancer. People who test positive for H. pylori are offered antibiotic treatment, and those with a positive family history or warning symptoms may be offered an upper endoscopy. The study tracks how many people complete each step, from returning the sample to finishing treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Helicobacter pylori stool antigen test combined with upper endoscopy for gastric cancer screening
What this could lead to
If it works, this could give health systems a practical way to screen for stomach cancer alongside bowel cancer, catching both diseases earlier in people over 50.
What could go wrong
The study measures whether people complete the screening steps, not whether it saves lives. Many invited individuals may not return stool samples, and the approach may not work equally well across different European health systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 8,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

National healthcare screening databases will be utilized for selecting study participants. The study population will generally be selected from a pre-defined geographical area to ensure access to necessary study facilities. The following regions have been identified as initial study centres: Original pilot sites Estonia - Tallinn city and Harjumaa municipality; Italy (Marche) - Marche Region - Macerata District; Latvia - Riga city, Jēkabpils region and Aizkraukle, Madona, Varakļāni, Līvāni municipalities; Portugal - North of Portugal, Santo Tirso (Medio Ave Local Health Unit; Barcelos-Esposende Local Health Unit). Additional pilot sites Italy (Bologna) - Emilia-Romagna Region - Bologna District; Lithuania - Vilnius city municipality.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 50 years and above (the actual recruitment age corresponds to the first CRC-screening age in each participating country/region); Exclusion Criteria: * personal history of gastric cancer; * personal history of colorectal cancer; * successfully screened via national colorectal cancer screening programme; * inability or unwillingness to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm gastric cancer gastric neoplasm Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Gastric cancer Helicobacter pylori infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.